Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.
Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China.
Semin Arthritis Rheum. 2024 Aug;67:152483. doi: 10.1016/j.semarthrit.2024.152483. Epub 2024 May 31.
Rapidly progressive interstitial lung disease (RPILD) in patients with dermatomyositis (DM) significantly impacts prognosis, leading to high mortality rates. Although several indicators have been demonstrated to strongly correlate with the risk of developing RPILD, their clinical utility still needs to be investigated. The objective of this study was to investigate the clinical significance of soluble CXCL16 (sCXCL16) in DM patients complicated with RPILD.
Serum sCXCL16 was measured by enzyme-linked immunosorbent assay in 96 patients with DM and 55 matching healthy donors. Correlations between sCXCL16 levels and clinical features, laboratory examinations and the predictive value of baseline sCXCL16 level for RPILD were analysed.
The serum sCXCL16 levels were significantly higher in patients with DM (n = 96, 3.264 ± 1.516 ng/mL) compared with healthy donors (n = 55, 1.781 ± 0.318 ng/mL), especially in DM complicated with RPILD (n = 31, 4.441 ± 1.706 ng/mL). The sCXCL16 levels were positively correlated with levels of serum ferritin, C reactive protein, erythrocyte sedimentation rate, lactate dehydrogenase, hydroxybutyrate dehydrogenase, and negatively correlated with peripheral lymphocytes percentage, but showed no correlation with levels of anti-melanoma differentiation-associated gene 5 antibody, Krebs von den Lungen-6 or creatine kinase. Multivariable analysis showed that elevated sCXCL16 was an independent prognostic factor for poor prognosis of RPILD in patients with DM. The 2-year survival rate was significantly lower in patients with high sCXCL16 level than in those with low sCXCL16 level.
A higher serum sCXCL16 level was identified as a predictive biomarker of RPILD in patients with DM, and closely associated with poor prognosis.
皮肌炎（DM）患者快速进展性间质性肺病（RPILD）显著影响预后，导致死亡率高。虽然已经证实了几种指标与发生 RPILD 的风险强烈相关，但它们的临床实用性仍需进一步研究。本研究旨在探讨可溶性 CXCL16（sCXCL16）在 DM 合并 RPILD 患者中的临床意义。
采用酶联免疫吸附试验检测 96 例 DM 患者和 55 例匹配的健康供者的血清 sCXCL16。分析 sCXCL16 水平与临床特征、实验室检查的相关性，以及基线 sCXCL16 水平对 RPILD 的预测价值。
与健康供者（n=55，1.781±0.318ng/ml）相比，DM 患者（n=96，3.264±1.516ng/ml）血清 sCXCL16 水平显著升高，尤其是 DM 合并 RPILD 患者（n=31，4.441±1.706ng/ml）。sCXCL16 水平与血清铁蛋白、C 反应蛋白、红细胞沉降率、乳酸脱氢酶、羟丁酸脱氢酶水平呈正相关，与外周血淋巴细胞百分比呈负相关，与抗黑色素瘤分化相关基因 5 抗体、Krebs von den Lungen-6 或肌酸激酶水平无相关性。多变量分析显示，sCXCL16 升高是 DM 患者 RPILD 预后不良的独立预测因素。sCXCL16 水平较高的患者 2 年生存率明显低于 sCXCL16 水平较低的患者。
血清 sCXCL16 水平升高可作为 DM 患者发生 RPILD 的预测生物标志物，与预后不良密切相关。
